Histrelin: Uses, Mechanism, and Side Effects

Parents of a child diagnosed with early puberty often want to understand how a single implant can pause its progression for a year at a time. Histrelin, marketed as Supprelin LA, is the subcutaneous implant many pediatric endocrinologists turn to for this purpose.

Key takeaways

• Histrelin is a GnRH agonist delivered through a subcutaneous implant, sold as Supprelin LA.
• It is approved to treat central precocious puberty (CPP) in children.
• The label does not carry a boxed warning.
• 16 registered trials include studies of histrelin implants in advanced prostate cancer, a related off-label use of the same mechanism.
• FAERS reports on histrelin are dominated by device and procedural issues rather than classic drug side effects.

What Histrelin Is

Histrelin belongs to the GnRH agonist class. Once implanted, it releases roughly 65 mcg of histrelin acetate per day on a continuous basis. Continuous exposure initially stimulates the pituitary gland but then desensitizes it, reducing the gonadotropin signals that drive ovarian and testicular hormone production. The practical result is a suppression of sex steroid output as long as the implant remains in place.

What Histrelin Is Approved For

Supprelin LA is approved for children with central precocious puberty, a condition marked by secondary sexual characteristics appearing before age 8 in girls or age 9 in boys. The label notes that CPP can also advance bone age faster than chronological age, which may reduce eventual adult height if untreated. Diagnosis is expected to be confirmed with hormone testing and bone age assessment before treatment begins. No boxed warning appears on this label.

What the Evidence Shows

Histrelin's clinical development spans 16 registered trials. Among the trials on record, a completed Phase 3 study evaluated the efficacy and safety of a histrelin subdermal implant in men with advanced prostate cancer, reflecting how the same GnRH agonist mechanism has been studied outside the pediatric CPP indication. A separate completed observational study also followed patients using a histrelin implant (Vantas) for advanced prostate cancer.

Reported Side Effects

FAERS data represent adverse event reports, not confirmed incidence or proven causation. The most frequently reported issues for histrelin relate to the implant and its administration rather than systemic drug effects: drug ineffective (138 reports), device breakage (117), and procedural complication (83). Reports also describe incorrect drug or product administration duration (65 and 60, respectively). Skin reactions appear as well, including rash (46) and implant site rash (41), along with headache (39).